Is zinc-alpha 2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis?


Autoria(s): Leal, Viviane O.; Lobo, Julie C.; Stockier-Pinto, Milena B.; Farage, Najla E.; Abdalla, Dulcineia Saes Parra; Leite Junior, Maurilo; Mafra, Denise
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

Background: Zinc-alpha 2-glycoprotein (ZAG) is a lipid mobilizing factor. Its anti-inflammatory action and expression pattern suggest that ZAG could act by protecting against the obesity-associated disorders. In hemodialysis (HD) patients, ZAG levels were described to be elevated but its effects on markers of inflammation and LDL oxidation are still unclear. We investigated the relationship between ZAG and markers of systemic inflammation and LDL atherogenic modification profile in HD patients. Methods: Forty-three patients regularly on HD were studied and compared to 20 healthy subjects. Plasma ZAG, adiponectin, electronegative LDL [LDL(-)], an atherosclerotic negatively charged LDL subtraction, and anti-LDL(-) autoantibodies levels were measured by ELISA. Markers of inflammation and atherogenic cell recruitment (TNF-alpha, interleukin-6, VCAM-1, ICAM-1, MCP-1 and PAI-1) were also determined. Results: Inflammatory markers and atherogenic cell recruitment were higher in HD patients when compared to healthy subjects. ZAG levels were also higher in HD patients (151.5 +/- 50.1 mg/l vs 54.6 +/- 23.0 mg/l; p<0.0001) and its levels were negatively correlated with TNF-alpha (r= -0.39; p = 0.001) and VCAM-1 (r= -0.52; p<0.0001) and, positively correlated with anti-LDL(-) autoantibodies (r = 038; p = 0.016). On multivariate analyses, plasma ZAG levels were independently associated with VCAM-1 (p = 0.01). Conclusion: ZAG is inversely associated with markers of pro-atherogenic factors linked to systemic inflammation and oxidative stress. Thus, this adipokine may constitute a novel marker of a favorable metabolic profile regarding cardiovascular risk factors in HD population. (C) 2011 Elsevier B.V. All rights reserved.

Conselho Nacional de Pesquisa (CNPq)

Conselho Nacional de Pesquisa (CNPq)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Identificador

CLINICA CHIMICA ACTA, AMSTERDAM, v. 413, n. 41430, p. 616-619, 44621, 2012

0009-8981

http://www.producao.usp.br/handle/BDPI/37363

10.1016/j.cca.2011.12.002

http://dx.doi.org/10.1016/j.cca.2011.12.002

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

AMSTERDAM

Relação

CLINICA CHIMICA ACTA

Direitos

closedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #ADIPOKINE #ATHEROSCLEROSIS #HEMODIALYSIS #INFLAMMATION #ZINC-ALPHA 2-GLYCOPROTEIN #LOW-DENSITY-LIPOPROTEIN #LIPID-MOBILIZING FACTOR #CHRONIC-RENAL-FAILURE #ADIPOSE-TISSUE #ELECTRONEGATIVE-LDL #ADHESION MOLECULES #ENDOTHELIAL-CELLS #PLASMA-PROTEIN #ADIPOCYTES #ADIPONECTIN #MEDICAL LABORATORY TECHNOLOGY
Tipo

article

original article

publishedVersion